'Chinese Peptides,' Explained With Data: Imports, Crypto Payments and What Testing Finds
Last updated: November 4, 2026 · 10 min read · By the Grey Peptides Editorial Board
- 'Chinese peptides' is not a kind of molecule. It is shorthand for unapproved peptides made by overseas chemical manufacturers and sold directly to consumers, most often labelled for research use only.
- Blockchain analysis traced $32 million in crypto to gray-market peptide vendors in the first quarter of 2026, up 159% on the quarter before and on course for a $100 million-plus year. In 2024 the figure was about $1 million a quarter.
- As the market grew, buyers stopped testing. Spending on independent purity testing fell an estimated 88% per buyer, and vendor certificates usually report purity, not sterility.
- Some of the suppliers traced on-chain had previously sold fentanyl and amphetamine precursors. Customs import figures, by contrast, cover a broad legal category and do not measure the gray market at all.
What 'Chinese peptides' means
The phrase describes a supply route, not a substance. It refers to peptides, mostly unapproved ones such as BPC-157 or the investigational weight-loss drug retatrutide, made by chemical manufacturers abroad and sold directly to individual buyers rather than through pharmacies; Chainalysis reports that many of the top gray-market vendors are themselves Chinese chemical manufacturers 1. The products are typically labelled 'for research use only' or 'not for human consumption', a label FDA has said does not change what a product is when it is marketed for people 2.
What is unusual is the last step. Instead of selling a bulk ingredient to a regulated manufacturer, a supplier sells a finished vial to a person, who injects it. Everything regulation normally inserts between those two points, from sterility testing to identity checks to a label a doctor can trust, is missing.
The numbers below come from three kinds of source: trade data, blockchain analysis and laboratory testing. Each measures something different, and none of them measures the whole market.
What the import data does and does not show
The most-quoted figure comes from U.S. customs data cited by The New York Times in January 2026: imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, from $164 million in the same period of 2024 3.
That number is easy to misread. The Times describes the category as including demand for GLP-1 drugs, melanotan II and other peptides from compounding pharmacies as well as gray-market suppliers 3. A customs total for a category does not say which importer each shipment went to, or how much of it reached consumers.
So the doubling tells you that the flow of these compounds from China grew sharply. It does not tell you how much of that flow ended up in someone's arm outside the regulated system. For that, the clearest available evidence is not trade data at all, but the money trail.
Following the money: the blockchain data
Banks and card processors often prohibit the sale of prescription-grade compounds, and Chainalysis describes cryptocurrency as the market's backbone for that reason 1. That choice left a public record. In June 2026 the blockchain analytics firm Chainalysis published an analysis of payments to wallets it attributes to peptide vendors 1.
For much of 2024, those wallets received roughly $1 million a quarter. In the first quarter of 2026 they received $32 million, which the report calls a 159% rise from $12 million in the fourth quarter of 2025 (by simple arithmetic the rise is about 167%), after six consecutive quarters of growth. The firm projected about $39 million for the second quarter, putting the market above a $100 million annual run rate 1.
Chainalysis describes three eras. Before 2025, inflows averaged about $200,000 a month. Growth in 2025 coincided with the attention around Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, which the firm notes without claiming a cause: on-chain data alone cannot establish one. Then, in late 2025, demand surged as a social-media subculture focused on physical appearance adopted peptides, and the monthly average rose to about $9.9 million, with peak months above $10 million 1.
Two details in the June 2026 report describe how the trade has professionalised. Larger vendors rely almost entirely on bitcoin and stablecoins, and among vendors averaging $1,000 or more per deposit, stablecoins make up the majority, which shields wholesale orders from crypto's price swings. And the report describes buyers as often inexperienced with both unregulated drugs and cryptocurrency, and says requests from likely underage users for help getting around identity checks are increasingly common 1.
Why paying in crypto made the market visible
There is an irony at the centre of the data. Vendors adopted cryptocurrency because the banking system would not serve them, and that choice put their entire revenue on a public ledger. A bitcoin or stablecoin payment sits on a public ledger, visible to anyone who can attribute the wallets.
That is how a private analytics firm could measure the market quarter by quarter, link vendor wallets to their suppliers, and spot a former fentanyl-precursor supplier reappearing under a new corporate name 1. It also limits what the numbers can show: a count of crypto payments to attributed wallets cannot include vendors paid by bank transfer, payment apps or cash, or wallets no one has attributed. That limit is our reading of the method; the report does not state it.
Reading the numbers carefully
The report states its quarterly change as a 159% rise on the previous quarter and does not state a year-on-year percentage; some of its estimates rest on wallets it describes as suspected, and on its own attribution 1. Figures in news coverage that the report does not contain are not repeated here. The figures on this page are the report's own, read directly, and we would rather give a smaller number we can source than a larger one we cannot.
What testing finds, and why buyers stopped doing it
The gray market's informal safeguard has been independent testing: buyers sending a vial to a laboratory to check that it contains what the label says. Chainalysis traced payments to wallets it suspects belong to one Czech laboratory used for this, which have received more than $12 million since 2023 1.
The striking finding is the trend. In the market's earlier eras, many buyers paid to retest what was shipped to them. By the late-2025 boom, testing spend per buyer had fallen an estimated 88%, to about $8, by the firm's own attribution of wallets. The laboratory is busier than ever, with monthly inflows rising from about $187,000 to about $502,000, because there are far more buyers; each of them is simply testing far less. Many now rely on certificates the vendor supplies 1.
Those certificates have a specific blind spot. A mass and purity result answers whether the vial contains the right molecule; the report warns that such certificates may not test for sterility, which answers whether injecting it could cause an infection. The report describes a batch of retatrutide that carried a passing purity certificate and then failed an independent sterility test submitted by a cautious buyer 1.
Peer-reviewed laboratory work points the same way. European medicines-control laboratories examining suspected illegal health products recorded 1,104 cases from 16 countries between 2017 and 2019, 83% of them from the illegal market, and research peptides were the second most reported category, at 11% of samples 4. A European medicines-control laboratory identified the research peptides Selank and Semax, which to its knowledge had not completed any clinical trials, in seized preparations and noted how freely they could be bought online 5. And an analysis of two commercially sourced custom peptides found 20% and 43% by weight of an undeclared substance, mannitol, which is UV-transparent and can be missed by routine liquid-chromatography quality control 6.
What happens to people who use them
Case reports are not statistics, but they show the failure modes. In 2026, doctors reported an 18-year-old woman who developed euglycaemic ketoacidosis, a dangerous acid build-up with near-normal blood sugar, ten days after starting semaglutide bought online and escalating the dose without supervision 7. Another report described a man with type 1 diabetes who developed impending ketoacidosis and acute kidney injury shortly after injecting an online product sold as retatrutide; the authors noted that the composition, purity and dose of such products are uncertain 8.
Neither report shows that the product was contaminated, and in the second the patient also had Shigella gastroenteritis, so the authors could not separate the infection's effects from the drug's 8. What they show is the second danger the gray market creates beyond quality: drugs with real, potent effects taken without the assessment, dose titration and follow-up that come with a prescription. Retatrutide, in particular, is not approved anywhere as of October 27, 2026 9, and in its phase 2 trial the 8 mg and 12 mg doses were reached by starting at 2 mg or 4 mg and escalating 10.
Who is on the other end
The most serious finding in the blockchain data concerns the suppliers. It is important to say, as the report itself does, that not every overseas laboratory has such connections; many are standard chemical manufacturers 1.
But some do. Chainalysis traced wallets belonging to Chinese chemical companies previously identified as suppliers of fentanyl and amphetamine precursors, which had received funds from darknet drug vendors and, in one case, from a cartel-linked money-laundering operation. As enforcement against precursor trafficking tightened through 2024, at least two of these companies began selling peptides directly to retail buyers, in one case using the same contact number as their precursor listings, and in another through a separately named corporate alter-ego 1.
The economic logic is plain. Selling precursors, a supplier is a wholesaler and the cartel takes the retail margin. Selling a finished peptide to a consumer, the supplier keeps the whole margin and faces less legal risk. For a buyer, the point is simpler: the label on a research-chemical vial says nothing about who made it, and the money sent for it can reach people a buyer would never knowingly deal with.
What this means if you are considering it
Every source on this page agrees on the core facts: the market is growing quickly, buyers are testing less, the products are unregulated, and some suppliers have links to drug trafficking. What none of them can tell you is whether a particular vial is safe, because nothing in the system is designed to answer that.
Some of the compounds sold this way have approved versions. Semaglutide and tirzepatide are available on prescription, and our guides compare them with what the trials found. Others, such as BPC-157, have no approved version and cannot lawfully be compounded by a US pharmacy as of October 27, 2026, because its nomination was withdrawn from Category 2 and FDA's list places it in no category 11,12; our BPC-157 access guide explains why. Still others, such as retatrutide, are in late-stage trials and approved nowhere.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 13. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
Our guide to research-use-only labels covers what that phrase does and does not mean, and the certificate decoder explains how to read a certificate of analysis, including what a purity certificate leaves out.
Frequently asked questions
What are 'Chinese peptides'?
Not a type of molecule but a supply route: unapproved peptides made by overseas chemical manufacturers, mostly in China, and sold directly to consumers, usually labelled for research use only.
Are peptides from China safe?
There is no way to know for a particular vial. They are unregulated, buyers have largely stopped independent testing, and vendor certificates may not test for sterility.
How big is the gray market for peptides?
No dataset measures it fully. Blockchain analysis traced $32 million in crypto to peptide vendors in the first quarter of 2026 and projected a $100 million-plus year, which covers crypto payments only.
Do customs figures measure the gray market?
No. The $328 million figure for 2025 covers a broad legal category of hormone and peptide imports, including ingredients for approved drugs, and cannot separate those from consumer parcels.
Are gray-market peptides linked to drug trafficking?
Some are. Blockchain analysis traced at least two peptide sellers to Chinese companies previously identified as fentanyl and amphetamine precursor suppliers, though not every overseas manufacturer has such a link.
Related on Grey Peptides
- What research use only means
- Can a doctor prescribe BPC-157 in 2026?
- Certificate of analysis decoder
- Retatrutide encyclopedia entry
- Regulatory tracker
Sources
- Chainalysis Team. The $100 Million Crypto 'Looksmaxxing' Boom: How Chinese Cartel Suppliers Pivoted to the Gray-Market Peptide Ecosystem. Chainalysis blog, June 4, 2026 (modified June 5, 2026); read September 30, 2026, re-read October 27 and October 28, 2026 (every figure on this page found in the report's text, including the estimated 88% fall in testing spend to $8 per buyer). Cited without a link.
- U.S. Food and Drug Administration (December 10, 2024). Warning letter 694608 to an online seller of peptides labelled 'for research use only': the disclaimers do not override evidence that the products are intended for human use.
- Sun, J., Henry, J. and Agosta, H. 'Chinese Peptides' Are the Tech World's Latest Biohacking Fad. The New York Times, January 3, 2026 (republished by GV Wire, January 7, 2026; re-read October 27, 2026); U.S. customs figures as the article gives them. Cited without a link.
- Deconinck, E. et al. (2021). The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Test Anal. PMID: 33453144
- Vanhee, C. et al. (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. PMID: 31667971
- Choules, M. P. et al. (2020). NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal. PMID: 31671336
- Sterckx, M. et al. (2026). Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. Cureus. PMID: 41773123
- Branine, N. (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. PMID: 42669023
- Eli Lilly and Company (August 12, 2026). Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. News release: no regulator has approved a retatrutide medicine. Cited without a link: we name manufacturers but do not link to them.
- Jastreboff, A. M. et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PMID: 37366315
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: BPC-157 among the nominations withdrawn from Category 2. Content current as of April 22, 2026; read October 27, 2026. FDA
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, with the interim category list (fda.gov/media/94155, Updated May 14, 2026; BPC-157 in no category). Read October 27, 2026. FDA
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. This article reports market data and published findings; it does not name or link to any seller, and it is not medical advice.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead